CAR-T Long Term Follow Up (LTFU) Study Post author: Post published:April 20, 2026 Post category: Continue ReadingCAR-T Long Term Follow Up (LTFU) Study
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Post author: Post published:April 20, 2026 Post category: Continue ReadingLong-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) Post author: Post published:April 20, 2026 Post category: Continue ReadingT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma Post author: Post published:April 20, 2026 Post category: Continue ReadingCS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingAnti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax Post author: Post published:April 20, 2026 Post category: Continue ReadingCirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingStudy of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
